Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Inhibrx Biosciences, Inc. (INBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/16/2025: INBX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 33.86% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 220.18M USD | Price to earnings Ratio 0.13 | 1Y Target Price 12 |
Price to earnings Ratio 0.13 | 1Y Target Price 12 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 10.80 - 17.79 | Updated Date 06/22/2025 |
52 Weeks Range 10.80 - 17.79 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 119.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 861485.5% | Operating Margin (TTM) -116231.5% |
Management Effectiveness
Return on Assets (TTM) -107.28% | Return on Equity (TTM) 41.18% |
Valuation
Trailing PE 0.13 | Forward PE - | Enterprise Value 110188499 | Price to Sales(TTM) 1100.89 |
Enterprise Value 110188499 | Price to Sales(TTM) 1100.89 | ||
Enterprise Value to Revenue 550.94 | Enterprise Value to EBITDA 0.06 | Shares Outstanding 14475900 | Shares Floating 7712906 |
Shares Outstanding 14475900 | Shares Floating 7712906 | ||
Percent Insiders 27.19 | Percent Institutions 68.12 |
About Inhibrx Biosciences, Inc.
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2024-05-29 | Founder, CEO & Chairman Mr. Mark Paul Lappe | ||
Sector Healthcare | Industry Biotechnology | Full time employees 156 | Website https://inhibrx.com |
Full time employees 156 | Website https://inhibrx.com | ||
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.